NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, today announced that it is sponsoring an educational workshop and dinner on new ideas for lid management during the ASCRS Annual Symposium at the San Diego Convention Center in San Diego, Calif., April 17-21.
The workshop will describe using Avenova™ to improve lid hygiene regimens for such common eye conditions as blepharitis and dry eye, and for preparing eyes for surgery. The featured speakers will be:
– Arthur Epstein, O.D., F.A.A.O., co-founder of Phoenix Eye Care and head of the practice’s Dry Eye – Ocular Surface Disease Center. He serves as an Adjunct Associate Professor at Midwestern University, Arizona College of Optometry Institute, and is the contributing editor for Review of Optometry, executive editor of Review of Cornea and Contact Lenses, and founder and chief medical editor of Optometric Physician.
– Terrence O’Brien, M.D., director of the Refractive Surgery Service at the University of Miami Miller School of Medicine’s Bascom Palmer Eye Institute, and Charlotte Breyer Rodgers Chair in Ophthalmology. He previously served for 15 years as the Tom Clancy Professor of Ophthalmology and Director of Refractive Surgery and Ocular Infectious Diseases at Wilmer Eye Institute of Johns Hopkins University School of Medicine in Baltimore.
The workshop and dinner will be held Sunday, April 19, from 7-10 p.m. in the Ocean Room at the Convention Center.
“Dr. Epstein and Dr. O’Brien are among the nation’s most prominent eye care specialists and we are excited about their participation in our workshop,” said Ron Najafi, Ph.D., Chairman and CEO of NovaBay. “They will be sharing their first-hand experiences with Avenova and how it is making major improvements in eye care and the quality of life for patients with chronic eyelid conditions.”
As the speakers will describe at the workshop, millions of Americas suffer from chronic conditions like blepharitis, where bacteria grow on the lids and cause inflammation, irritation, and a crusty build-up.
“These conditions have become increasingly difficult to treat,” explained Dr. O’Brien. “Traditional treatments, such as using antibiotics and cleaning with baby shampoo, are not ideal. Antibiotic use promotes resistance to the drugs, while the shampoo can be irritating and ineffective.”
“That’s why Dr. Epstein and Dr. O’Brien are enthusiastic about a new approach—wiping the eye lids with NovaBay’s Avenova,” added Dr. Najafi. “Avenova is the only lid cleanser to contain pure hypochlorous acid, a naturally occurring substance produced by white blood cells to fight microbial invaders.”
“Avenova safely removes the bacteria and the crusty material, providing relief to patients,” said Dr. Epstein. “It has been a phenomenal, phenomenal addition to our armamentarium.”
As Dr. O’Brien has explained at previous medical meetings, Avenova is not only causing a paradigm shift in the management of blepharitis and dry eye, it also has an important role to play in pre-operative lid hygiene procedures for surgery. “Avenova may help control several lid margin factors and contribute to putting the odds of safer surgery in favor of the physician,” added Dr. O’Brien.
To reserve your seat for the workshop and dinner, RSVP to firstname.lastname@example.org
And to meet the NovaBay Team and learn more about Avenova, visit booth 360 at ASCRS.
Avenova* is the only eye care product to contain Neutrox™, NovaBay’s proprietary, pure hypochlorous acid (HOCl) with all the bleach (sodium hypochlorite) impurities taken out. HOCl is a naturally occurring substance produced by white blood cells to fight microbial invaders. In Solution tests show it has potent antimicrobial activity and yet is non-toxic to mammalian cells. Laboratory tests demonstrate Neutrox neutralizes bacterial toxins in vitro. Avenova is uniquely suited for daily use by the millions of Americans who suffer from chronic eye conditions like blepharitis and dry eye. It is the only such product designed for continuous daily eyelid hygiene.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals is a biopharmaceutical company focusing commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX™ Family of Products, including AVENOVA™ for the eye care market and NEUTROPHASE® for wound care, which was initially cleared by FDA, and CELLERX™ for the dermatology market; and its AGANOCIDE® compounds, led by AURICLOSENE™. NovaBay is partnered in the U.S. and around the globe with: PBE, Inc. (USA), IHT, Inc. (USA), Galderma (France), Virbac (France), China Pioneer Pharma (China and Southeast Asia), Shin Poong Pharmaceuticals (South Korea), Biopharm (North African and Middle East), Sarmedic Ltd (Israel) and Alpha Pharma LLC (Ukraine).
*Avenova Skin and Wound Cleanser is intended for use under the supervision of healthcare professionals for cleansing and removal of foreign material, including microorganisms and debris from wounds, and for moistening absorbent wound dressings and cleaning minor cuts, minor burns, superficial abrasions and minor irritations of the skin. It is also intended for moistening and debriding acute and chronic dermal lesions, such as Stage I to IV pressure ulcers, stasis ulcers, leg ulcers, diabetic foot ulcers, post-surgical wounds, first and second degree burns, grafted and donor sites.
This news release contains “forward-looking statements.” The forward-looking statements include statements regarding Avenova’s commercial acceptance in the marketplace and the anticipated future financial performance of the Company. NovaBay does not provide guidance on future sales and no statement in this news release should be construed as a financial forecast or as guidance on sales for future periods. All statements in this news release are based on management’s current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Other risks relating to the company and its products, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” NovaBay undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Stay informed on NovaBay’s progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website
For NovaBay Avenova purchasing information, please contact:
Toll Free: 1-800-890-0329
At the Company
Thomas J. Paulson
Chief Financial Officer
Contact Thomas Paulson